Cellosaurus logo
expasy logo

Cellosaurus FM28 (CVCL_C583)

[Text version]
Cell line name FM28
Synonyms FM-28; FM 28
Accession CVCL_C583
Resource Identification Initiative To cite this cell line use: FM28 (RRID:CVCL_C583)
Comments Omics: Array-based CGH.
Derived from site: Metastatic; Skin; UBERON=UBERON_0002097.
Sequence variations
HLA typing Source: PubMed=7656272
Class I
HLA-AA*01,02
HLA-BB*08,15

Source: PubMed=15592718
Class I
HLA-AA*01:01,02:01
HLA-BB*08:01,15:01:01:01
HLA-CC*07:01:01,07:02
Class II
HLA-DPDPB1*04:01,01:01:01
HLA-DQDQB1*03:02,02:01
HLA-DRDRB1*04:01:01,03:01:01
Disease Cutaneous melanoma (NCIt: C3510)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_UI33 (FM28.4)
Sex of cell Male
Age at sampling Age unspecified
Category Cancer cell line
STR profile Source(s): ECACC=13012412; ESTDAB=ESTDAB-006

Markers:
AmelogeninX,Y
CSF1PO13
D3S135815
D5S81811,12
D7S82010,14
D13S31712
D16S53911,13
FGA22,24
TH016
TPOX8 (ESTDAB=ESTDAB-006)
9.3 (ECACC=13012412)
vWA16,17

Run an STR similarity search on this cell line
Publications

PubMed=7656272; DOI=10.1007/BF01527402
Kirkin A.F., Petersen T.R., Olsen A.C., Li L., thor Straten P., Zeuthen J.
Generation of human-melanoma-specific T lymphocyte clones defining novel cytolytic targets with panels of newly established melanoma cell lines.
Cancer Immunol. Immunother. 41:71-81(1995)

PubMed=8665567; DOI=10.1007/s002620050272
Kirkin A.F., thor Straten P., Zeuthen J.
Differential modulation by interferon gamma of the sensitivity of human melanoma cells to cytolytic T cell clones that recognize differentiation or progression antigens.
Cancer Immunol. Immunother. 42:203-212(1996)

PubMed=8968104
Bartkova J., Lukas J., Guldberg P., Alsner J., Kirkin A.F., Zeuthen J., Bartek J.
The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis.
Cancer Res. 56:5475-5483(1996)

PubMed=9288767
Guldberg P., thor Straten P., Birck A., Ahrenkiel V., Kirkin A.F., Zeuthen J.
Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma.
Cancer Res. 57:3660-3663(1997)

PubMed=15592718; DOI=10.1007/s00262-004-0561-5
Rodriguez T., Mendez R., Roberts C.H., Ruiz-Cabello Osuna F., Dodi I.A., Lopez-Nevot M.A., Paco L., Maleno I., Marsh S.G.E., Pawelec G., Garrido F.
High frequency of homozygosity of the HLA region in melanoma cell lines reveals a pattern compatible with extensive loss of heterozygosity.
Cancer Immunol. Immunother. 54:141-148(2005)

PubMed=17260012; DOI=10.1038/sj.onc.1210252
Jonsson G., Dahl C., Staaf J., Sandberg T., Bendahl P.-O., Ringner M., Guldberg P., Borg A.
Genomic profiling of malignant melanoma using tiling-resolution arrayCGH.
Oncogene 26:4738-4748(2007)

PubMed=23851445; DOI=10.1158/1541-7786.MCR-13-0006
Dahl C., Christensen C., Jonsson G., Lorentzen A., Skjodt M.L., Borg A., Pawelec G., Guldberg P.
Mutual exclusivity analysis of genetic and epigenetic drivers in melanoma identifies a link between p14 ARF and RARbeta signaling.
Mol. Cancer Res. 11:1166-1178(2013)

Cross-references
Cell line collections (Providers) ECACC; 13012412
Cell line databases/resources cancercelllines; CVCL_C583
ESTDAB; ESTDAB-006
Encyclopedic resources Wikidata; Q54835024
Gene expression databases GEO; GSM156041
Polymorphism and mutation databases Cosmic; 808545
Cosmic; 972279
Cosmic; 1047662
Cosmic; 2163766
IARC_TP53; 26089
Progenetix; CVCL_C583
Entry history
Entry creation22-Oct-2012
Last entry update02-May-2024
Version number23